Drug intelligence / Profile preview

GP2015

Development stage: Phase 3
Lead developer: Sandoz
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

GP2015 is an etanercept biosimilar developed by Sandoz. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human p75 TNF receptor linked to the Fc portion of human IgG1 antibody. GP2015 works by binding specifically to tumor necrosis factor (TNF) and inhibiting its biological activity, thereby reducing inflammatory processes. It has demonstrated bioequivalence to reference etanercept in terms of pharmacokinetics, efficacy, safety, and immunogenicity.

Brand names: Erelzi
Other names: Etanercept biosimilar

Targets

TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)

Beyond the preview

Go deeper on GP2015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GP2015.

Explore the full profile